[
1. Yang, P., Wang, X. COVID-19: a new challenge for human beings. Cell. Mol. Immunol. 2020, 17 (5), 555−557.
]Search in Google Scholar
[
2. Zumla, A., Chan, J. F. W., Azhar, E. I., et al. Coronaviruses − drug discovery and therapeutic options. Nat. Rev. Drug Discovery 2016, 15 (5), 327−347.
]Search in Google Scholar
[
3. Walls, A. C., Park, Y.-J., Tortorici, M. A., et al. Structure, Function, and Antigenicity of the SARSCoV-2 Spike Glycoprotein. Cell 2020, 181 (2), 281−292.e6.
]Search in Google Scholar
[
4. Xu, H., Zhong, L., Deng, J., et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int. J. Oral Sci. 2020, 12 (1), 8.
]Search in Google Scholar
[
5. Jia, H. P., Look, D. C., Shi, L., et al. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia. J. Virol. 2005, 79 (23), 14614.
]Search in Google Scholar
[
6. Hou, Y. J., Okuda, K., Edwards, C. E, et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell 2020, 182, 429.
]Search in Google Scholar
[
7. Tay, M. Z., Poh, C. M., Renia, L., et al. The trinity of COVID- 19: immunity, inflammation and intervention. Nat. Rev. Immunol. 2020, 20 (6), 363−374.
]Search in Google Scholar
[
8. Merrill, J. T., Erkan, D., Winakur, J., et al. A. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat. Rev. Rheumatol. 2020, 16 (10), 581−589.
]Search in Google Scholar
[
9. Whitsett, J. A., Alenghat, T. Respiratory epithelial cells orchestrate pulmonary innate immunity. Nat. Immunol. 2015, 16 (1), 27−35.
]Search in Google Scholar
[
10. Zhou, Z., Ren, L., Zhang, L., et al. Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection. SSRN Electronic Journal 2020, DOI: 10.2139/ssrn.3551623.
]Search in Google Scholar
[
11. Zhou, Z., Ren, L., Zhang, L., et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe 2020, 27 (6), 883−890.e2.
]Search in Google Scholar
[
12. Jamilloux, Y., Henry, T., Belot, A., et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anticytokine interventions. Autoimmun. Rev. 2020, 19 (7).
]Search in Google Scholar
[
13. Li, G., Fan, Y., Lai, Y., et al. Coronavirus infections and immune responses. J. Med. Virol. 2020, 92 (4), 424−432.
]Search in Google Scholar
[
14. Seif, F., Khoshmirsafa, M., Aazami, H., et al. The role of JAKSTAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun. Signaling 2017, 15 (1), 23.
]Search in Google Scholar
[
15. Channappanavar, R., Fehr, A. R., Vijay, R, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe 2016, 19 (2), 181−193.
]Search in Google Scholar
[
16. Juno, J. A., Tan, H.-X., Lee, W. S., et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020, 26, 1428.
]Search in Google Scholar
[
17. Greenhalgh, T., Knight, M., A’Court, et al. Management of post-acute covid-19 in primary care. BMJ. 2020, 370, m3026.
]Search in Google Scholar
[
18. Herold, T., Jurinovic, V., Arnreich, C et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID- 19. J. Allergy Clin. Immunol. 2020, 146 (1), 128−136.e4.
]Search in Google Scholar
[
19. Barnes, B. J., Adrover, J. M., Baxter-Stoltzfus, A., et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J. Exp. Med. 2020, 217 (6), No. e20200652.
]Search in Google Scholar
[
20. Cao, X. COVID-19: immunopathology and its implications for therapy. Nat. Rev. Immunol. 2020, 20 (5), 269−270.
]Search in Google Scholar
[
21. Maucourant, C., Filipovic, I., Ponzetta, A., et al. Natural killer cell immunotypes related to COVID-19 disease severity. Science Immunology 2020, 5 (50), No. eabd6832
]Search in Google Scholar
[
22. Gralinski, L. E., Sheahan, T. P., Morrison, T. E, et al. Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio 2018, 9 (5), e01753-18.
]Search in Google Scholar
[
23. Zhou, Y., Fu, B., Zheng, X., et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. National Science Review 2020, 7 (6), 998−1002.
]Search in Google Scholar
[
24. Onder, G., Rezza, G., Brusaferro, S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020, 323 (18), 1775−1776.
]Search in Google Scholar
[
25. Nikolich-Zugich, J., Knox, K. S., Rios, C. T., et al. SARSCoV- 2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience 2020, 42 (2), 505−514.
]Search in Google Scholar
[
26. Agrawal, A. Mechanisms and Implications of Age-Associated Impaired Innate Interferon Secretion by Dendritic Cells: A MiniReview. Gerontology 2013, 59 (5), 421−426.
]Search in Google Scholar
[
27. Chen, N., Zhou, M, Dong, X., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513.
]Search in Google Scholar
[
28. Patel, S. K., Velkoska, E., Burrell, L. M. Emerging markers in cardiovascular disease: Where does angiotensin-converting enzyme 2 fit in? Clin. Exp. Pharmacol. Physiol. 2013, 40 (8), 551−559.
]Search in Google Scholar
[
29. Takahashi, T., Ellingson, M. K., Wong, P., et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature 2020, DOI: 10.1038/s41586-020-2700-3.
]Search in Google Scholar
[
30. Zhou, F., Yu, T., Du, R., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020, 395 (10229), 1054−1062. (
]Search in Google Scholar
[
31. Greenhalgh, T., Knight, M., A’Court, C., et al. Management of post-acute covid-19 in primary care. BMJ. 2020, 370, m3026.
]Search in Google Scholar
[
32. Carfì, A., Bernabei, R., Landi, et al. Persistent Symptoms in Patients after Acute COVID-19. JAMA 2020, 324 (6), 603−605.
]Search in Google Scholar
[
33. Liu, j., Yang, X., Wang, H., et al. The analysis of the longterm impact of SARS-CoV-2 on the cellular immune system in individuals recovering from COVID-19 reveals a profound NKT cell impairment. medRxiv 2020, DOI: 10.1101/2020.08.21.20179358.
]Search in Google Scholar
[
34. Moldofsky, H., Patcai, J. Chronic widespread musculoskeletal pain, fatigue, depression and disordered sleep in chronic post-SARS syndrome; a case-controlled study. BMC Neurol. 2011, 11 (1), 37.
]Search in Google Scholar
[
35. Lee, K.-Y., Rhim, J.-W., Kang, J.-H. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2. Clin Exp Pediatr 2020, 63 (4), 117−118.
]Search in Google Scholar
[
36. Jeronimo, C. M. P., Farias, M. E. L., Val, F. F. A., et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Clin. Infect. Dis. 2020.
]Search in Google Scholar
[
37. Fadel, R., Morrison, A. R., Vahia, A., et al. Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19. Clin. Infect. Dis. 2020.
]Search in Google Scholar
[
38. Oxford, U. Low-cost dexamethasone reduces death by up to one third in hospitalized patients with severe respiratory complications of COVID-10; 2020.
]Search in Google Scholar
[
39. Group, T. R. C. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N. Engl. J. Med. 2020, DOI: 10.1056/NEJMoa2021436.
]Search in Google Scholar
[
40. Ogata, A., Tanaka, T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int. J. Rheumatol. 2012, 2012, 946048.
]Search in Google Scholar
[
41. Xu, X., Han, M., Li, T., et al. Effective treatment of severe COVID- 19 patients with tocilizumab. Proc. Natl. Acad. Sci. U. S. A. 2020; 117(20):10970-10975. doi:10.1073/pnas.2005615117
]Search in Google Scholar
[
42. Gritti, G., Raimondi, F., Ripamonti, D., et al. IL-6 signalling pathway inactivation with siltuximab in patients with COVID- 19 respiratory failure: an observational cohort study. medRxiv 2020, DOI: 10.1101/2020.04.01.20048561.
]Search in Google Scholar
[
43. De Luca, G., Cavalli C, Campochiaro C, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. The Lancet Rheumatology 2020, 2 (8), e465−e473.
]Search in Google Scholar
[
44. Temesgen, Z., Assi, M., Vergidis, P., et al. First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia. medRxiv 2020, DOI: 10.1101/2020.06.08.20125369.
]Search in Google Scholar
[
45. Cavalli, G.; Dinarello, C. A. Anakinra. Therapy for Non-cancer Inflammatory Diseases. Front. Pharmacol. 2018, 9, 1157.
]Search in Google Scholar
[
46. Cauchois, R., Koubi, M., Delarbre, D., et al. Early IL-1 receptor blockade in severe inflammatory respiratory failure complicating COVID-19. Proc. Natl. Acad. Sci. U. S. A. 2020, 117 (32), 18951.
]Search in Google Scholar
[
47. Dolinger, M. T., Person, H., Smith, R, et al. Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab. J. Pediatr. Gastroenterol. Nutr. 2020, 71 (2), 153−155.
]Search in Google Scholar
[
48. Catanzaro, M., Fagiani, F., Racchi, M. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2. Signal Transduct Target Ther 2020, 5, 84.
]Search in Google Scholar
[
49. Titanji, B. K., Farley, M. M., Mehta, A., et al. Use of Baricitinib in Patients with Moderate and Severe COVID-19. Clin. Infect. Dis. 2020, ciaa879.
]Search in Google Scholar
[
50. La Rosee, F., Bremer, H. C., Gehrke, I. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia 2020, 34 (7), 1805−1815.
]Search in Google Scholar
[
51. Dastan, F., Nadji, S. A., Saffaei, A., et al. Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial. Int. Immunopharmacol. 2020, 85, 106688−106688.
]Search in Google Scholar
[
52. Walz, L., Cohen, A. J., Rebaza, A. P., et al. Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis. medRxiv 2020, DOI: 10.1101/2020.08.10.20172189.
]Search in Google Scholar
[
53. Nimmerjahn, F., Ravetch, J. V. Anti-Inflammatory Actions of Intravenous Immunoglobulin. Annu. Rev. Immunol. 2008, 26 (1), 513−533.
]Search in Google Scholar
[
54. Cao, W., Liu, X., Bai, T., et al. High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infectious Diseases 2020, 7 (3), ofaa102.
]Search in Google Scholar
[
55. Shao, Z., Feng, Y., Zhong, L., et al. Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: A multicenter retrospective cohort study. medRxiv 2020, DOI: 10.1101/2020.04.11.20061739
]Search in Google Scholar
[
56. Li, L., Zhang, W., Hu, Y., et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044. Erratum in: JAMA. 2020 Aug 4;324(5):519.
]Search in Google Scholar
[
57. Joyner, M. J., Senefeld, J. W., Klassen, S. A., et al. Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19: Initial Three-Month Experience. medRxiv 2020, DOI: 10.1101/2020.08.12.20169359.
]Search in Google Scholar
